Free Nurse Practitioner CE

In this online, self-learning activity:

Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in older adults and a major driver of vision-related disability in high-income settings. In the United States, an estimated 18.3 million individuals have non–vision-threatening AMD and approximately 1.5 million have vision-threatening disease, creating substantial direct and indirect economic costs for patients, caregivers, and health systems. Late-stage AMD is commonly categorized as geographic atrophy (GA) or neovascular (or “wet”) AMD (nAMD); nAMD is characterized by macular neovascularization with exudation and/or hemorrhage that can rapidly compromise central vision if not controlled. Without timely therapy, vision decline after conversion to late-stage AMD may be clinically meaningful over weeks to months, and missed opportunities for early suppression can translate into avoidable functional loss.

In this online, self-learning activity:

Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular junction disorder marked by fluctuating, fatigable weakness that can involve ocular, bulbar, limb, and respiratory muscles. In a U.S. claims-based analysis, diagnosed prevalence in 2021 was 37.0 per 100,000 and incidence was 3.1 per 100,000, underscoring a clinically meaningful population at risk for disability and episodic deterioration. Reviews describe persistent symptom burden and functional consequences that extend beyond clinic-based strength testing. Real-world observational data link higher disease severity to greater impairment in activities of daily living, including reduced independence with self-care and mobility. International consensus guidance recommends stepwise management with early steroid-sparing intent and timely adjustment when treatment targets are not met. Higher severity is also associated with worse work productivity and activity impairment, amplifying socioeconomic burden.